Phase 1 Study of LY4057996 for Safety and Effects in Healthy Adults and Adults with Type 1 or Type 2 Diabetes

What this Trial Is About

Researchers are evaluating the safety, tolerability, and effects of LY4057996 in healthy adults and adults with Type 1 or Type 2 Diabetes. This Phase 1 study aims to understand how well the drug is tolerated and what side effects may occur. It also investigates how LY4057996 is absorbed and eliminated in the body through blood tests. The study is sponsored by Eli Lilly and Company and includes multiple parts with varying durations and participant groups. Participants will receive LY4057996 or placebo either subcutaneously under the skin or intravenously into a vein. Some groups may also receive other insulin treatments such as basal insulin, Lispro, or Degludec. The study is divided into several parts Part A lasts about 11 weeks, Parts A3 to A5 last about 4 weeks, Part B lasts about 6 weeks, and Part C lasts about 7 weeks, not including a screening period. Different parts include different dosing schedules and combinations of study drugs and insulin therapies. During the study, participants will undergo regular blood tests to measure drug levels and effects on glucose control. Researchers will monitor for any serious or related side effects throughout the study period, which can last up to 47 weeks. Other assessments include measuring fasting glucose and glucose infusion rates. Participants will be closely observed to ensure safety and to collect detailed information about how LY4057996 works in the body.

A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes